Thromboembolic events in paroxysmal vs. permanent non-valvular atrial fibrillation - Subanalysis of the J-RHYTHM registry

Circulation Journal

Volumn 78, Issue 10, 2014, Pages 2388-2393

  Inoue, Hiroshi ^a   Atarashi, Hirotsugu ^c   Okumura, Ken ^e   Yamashita, Takeshi ^d   Kumagai, Naoko ^f   Origasa, Hideki ^b  

^a TOYAMA UNIVERSITY HOSPITAL   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

^c NIPPON MEDICAL SCHOOL TAMA NAGAYAMA HOSPITAL   (Japan)

^d THE CARDIOVASCULAR INSTITUTE   (Japan)

^e HIROSAKI UNIVERSITY   (Japan)

^f KOCHI UNIVERSITY   (Japan)

Author keywords

Paroxysmal atrial fibrillation; Permanent atrial fibrillation; Risk factor; Thromboembolic event

Indexed keywords

ANTITHROMBOCYTIC AGENT; WARFARIN; ANTICOAGULANT AGENT;

AGED; AORTA ATHEROSCLEROSIS; ARTICLE; BRAIN INFARCTION; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MECHANICAL HEART VALVE; MITRAL VALVE STENOSIS; OBSERVATIONAL STUDY; PAROXYSMAL HEART ATRIUM FIBRILLATION; PERMANENT HEART ATRIUM FIBRILLATION; PERSISTENT HEART ATRIUM FIBRILLATION; POST HOC ANALYSIS; PROSPECTIVE STUDY; SINUS RHYTHM; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; ATRIAL FIBRILLATION; CLINICAL TRIAL; COMPLICATION; MULTICENTER STUDY; REGISTER; RISK FACTOR;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; THROMBOEMBOLISM; WARFARIN;

EID: 84908244794     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-14-0507     Document Type: Article

References (25)

1. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL; for the Stroke Prevention in Atrial Fibrillation Investigators. Stroke with intermittent atrial fibrillation: Incidence and predictors during aspirin therapy. J Am Coll Cardiol 2000; 35: 183-187.
2. Hohnloser SH, Pajitnev D, Pogue J, Healey JS, Pfeffer MA, Yusuf S, et al; for the ACTIVE W Investigators. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy. J Am Coll Cardiol 2007; 50: 2156-2161.
3. Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: Report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J 2010; 34: 967-975.
4. Nieuwlaat R, Dinh T, Olsson SB, Camm AJ, Capucci A, Tielman RG, et al; on behalf of the Euro Heart Survey Investigators. Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation? Eur Heart J 2008; 29: 915-922.
5. Disertori M, Franzosi MG, Barlera S, Cosmi F, Quintarelli S, Favero C, et al; on behalf of the GISI-AF Investigators. Thromboembolic event rate in paroxysmal and persistent atrial fibrillation: Data from the GISI-AF trial. BMC Cardiovasc Dis 2013; 13: 28.
6. Lip GYH, Frison L, Grind M; on behalf of the SPORTIF Investigators. Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation. J Intern Med 2008; 264: 50-61.
7. Al-Khatib SM, Thomas L, Wallentin L, Lopes RD, Gersh B, Garcia D, et al. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: Results from the ARISTOTLE trial. Eur Heart J 2013; 34: 2464-2471.
8. Inoue H, Atarashi H, Okumura K, Yamashita T, Origasa H, Kumagai N, et al; on behalf of the J-RHYTHM Registry Investigators. Impact of gender on the prognosis of patients with non-valvular atrial fibrillation. Am J Cardiol 2014; 113: 957-962.
9. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on Atrial Fibrillation. Chest 2010; 137: 263-272.
10. Fang MC, Singer DE, Chang Y, Hylek EM, Henault LE, Jensvold NG, et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: The AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation 2005; 112: 1687-1691.
11. Avgil Tsadok M, Jackevicius CA, Rahme E, Humphries KH, Behlouli H, Pilote L. Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation. JAMA 2012; 307: 1952-1958.
12. Friberg L, Benson L, Rosenqvist M, Lip GYH. Assessment of female sex as a risk factor in atrial fibrillation in Sweden: Nationwide retrospective cohort study. BMJ 2012; 344: e3522, doi:10.1136/bmj.e3522.
13. Atarashi H, Inoue H, Okumura K, Yamashita T, Origasa H; for the J-RHYTHM Registry investigators. Investigation of optimal anticoagulation strategy for stroke prevention in Japanese patients with atrial fibrillation: The J-RHYTHM Registry study design. J Cardiol 2011; 57: 95-99.
14. Atarashi H, Inoue H, Okumura K, Yamashita T, Kumagai N, Origasa H; for the J-RHYTHM Registry Investigators. Present status of anticoagulation treatment in Japanese patients with atrial fibrillation: A report from the J-RHYTHM Registry. Circ J 2011; 75: 2357-2362.
15. Inoue H, Okumura K, Atarashi H, Yamashita T, Origasa H, Kumagai N, et al; on behalf of the J-RHYTHM Registry Investigators. Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation: Results of the J-RHYTHM Registry. Circ J 2013; 77: 2264-2270.
16. Okumura K, Inoue H, Atarashi H, Yamashita T, Tomita H, Origasa H; for the J-RHYTHM registry investigators. Validation of CHA2DS2-VASc and HAS-BLED scores in Japanese patients with non-valvular atrial fibrillation. Circ J 2014; 78: 1593-1599.
17. J-RHYTHM Registry Investigators. Determinants of warfarin use and international normalized ratio levels in atrial fibrillation patients in Japan: Subanalysis of the J-RHYTHM Registry. Circ J 2011; 75: 2357-2362.
18. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870.
19. Camm AJ, Lip GYH, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focus update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation: Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747.
20. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focus update incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011; 57: e101-e198, doi:10.1016/j.jacc.2010.09.013.
21. Rosendaal FR, Cannegieter SC, van der Mer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-239.
22. Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation: The J-ROCKET AF study. Circ J 2012; 76: 2104-2111.
23. Komatsu T, Nakamura S, Suzuki O, Horiuchi D, Yomogida K, Okumura K. Long-term prognosis of patients with paroxysmal atrial fibrillation depends on their response to antiarrhythmic therapy. Circ J 2004; 68: 729-733.
24. Hunter RJ, McCready J, Diab I, Page SP, Finlay M, Richmond L, et al. Maintenance of sinus rhythm with an ablation strategy in patients with atrial fibrillation is associated with a low risk of stroke and death. Heart 2012; 98: 48-53.
25. Bunch TJ, May HT, Bair TL, Weiss JP, Crandall BG, Osborn JS, et al. Atrial fibrillation ablation patients have long-term stroke rate similar to patients without atrial fibrillation regardless of CHADS2 score. Heart Rhythm 2013; 10: 1272-1277.